JACC:AMI女性患者更应该加强对心脏疾病风险的认知

2015-10-27 崔倩 译 MedSci原创

在年轻急性心肌梗死(AMI)患者中,关于心脏危险因素,心脏风险感知的性别差异,以及有关的卫生保健提供者讨论的看法没有得到很好的研究。这项研究的目的是比较在住院治疗急性心肌梗死的男性和女性患者中,关于心脏危险因素普遍存在性,风险认知,卫生保健提供者的心脏疾病和风险修正的反馈意见的差异。研究人员共纳入了3,501例年龄18〜55岁的AMI患者于VIRGO研究中(在恢复中的变化:性别对年轻的AMI患者的

在年轻急性心肌梗死(AMI)患者中,关于心脏危险因素,心脏风险感知的性别差异,以及有关的卫生保健提供者讨论的看法没有得到很好的研究。

这项研究的目的是比较住院治疗的急性心肌梗死的男性和女性患者,关于心脏危险因素普遍存在性、风险认知、卫生保健提供者的心脏疾病和风险修正的反馈意见的差异。

研究人员共纳入了3,501例年龄18〜55岁的AMI患者于VIRGO研究中(在恢复中的变化:性别对年轻的AMI患者的影响),该研究在美国和西班牙医院于2008年8月和2012年1月之间进行,按性别比较了5个心脏危险因素的患病率。研究人员使用修改后的泊松回归来评估在心脏疾病风险的自我感知,自我报告提供者风险和修改讨论的性别差异。

几乎所有的患者(98%)都有≥1的危险因素,64%的患者危险因素≥3。只有53%的患者认为自己处于心脏疾病的危险中,甚至更少的患者报告被告知他们是在危险中(46%),或他们的卫生保健提供者讨论了心脏疾病和风险修正(49%)。和男性相比,较少的女性被告知她们处于风险中(相对风险:0.89;95%置信区间:0.84〜0.96),或者有一个卫生保健提供者来探讨风险修正(相对风险:0.84;95%置信区间:0.79〜0.89 )。风险的自我感知在男女之间没有什么区别。

尽管有显著心脏危险因素,但只有一半的年轻AMI患者在事件发生之前认为他们处在心脏疾病的风险中。更少的参与者能够和他们的卫生保健提供者讨论他们的风险或风险修正;在这方面女性表现的更为明显。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1853434, encodeId=6158185343408, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 14:55:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033491, encodeId=2e0d20334918c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri May 20 08:55:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325129, encodeId=c6ab132512923, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395344, encodeId=938f1395344fd, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472975, encodeId=55c414e297533, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41698, encodeId=779541698fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:03:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2016-09-07 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1853434, encodeId=6158185343408, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 14:55:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033491, encodeId=2e0d20334918c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri May 20 08:55:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325129, encodeId=c6ab132512923, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395344, encodeId=938f1395344fd, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472975, encodeId=55c414e297533, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41698, encodeId=779541698fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:03:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1853434, encodeId=6158185343408, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 14:55:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033491, encodeId=2e0d20334918c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri May 20 08:55:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325129, encodeId=c6ab132512923, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395344, encodeId=938f1395344fd, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472975, encodeId=55c414e297533, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41698, encodeId=779541698fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:03:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1853434, encodeId=6158185343408, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 14:55:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033491, encodeId=2e0d20334918c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri May 20 08:55:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325129, encodeId=c6ab132512923, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395344, encodeId=938f1395344fd, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472975, encodeId=55c414e297533, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41698, encodeId=779541698fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:03:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1853434, encodeId=6158185343408, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 14:55:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033491, encodeId=2e0d20334918c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri May 20 08:55:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325129, encodeId=c6ab132512923, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395344, encodeId=938f1395344fd, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472975, encodeId=55c414e297533, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41698, encodeId=779541698fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:03:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1853434, encodeId=6158185343408, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 14:55:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033491, encodeId=2e0d20334918c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Fri May 20 08:55:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325129, encodeId=c6ab132512923, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395344, encodeId=938f1395344fd, content=<a href='/topic/show?id=562b51588e6' target=_blank style='color:#2F92EE;'>#心脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51588, encryptionId=562b51588e6, topicName=心脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=49022500195, createdName=12498e0fm78暂无昵称, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1472975, encodeId=55c414e297533, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Thu Oct 29 03:55:00 CST 2015, time=2015-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=41698, encodeId=779541698fe, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b911658392, createdName=梦想天空, createdTime=Wed Oct 28 09:03:00 CST 2015, time=2015-10-28, status=1, ipAttribution=)]
    2015-10-28 梦想天空

    0

相关资讯

长城会 2014:常见急诊危重症如何处理?

随着急性心肌梗死(AMI)等重大急症发病年龄日趋年轻化,急诊危重症近年来受到越来越多的关注。今年长城会也加重了急诊危重症论坛的分量,日程由原来的1天增加到现在的3.5天,除了学术报告外,还有一系列病例讨论和培训工坊,内容丰富实用。 高龄AMI患者早期如何再灌注治疗 AMI已成为老年患者死亡的主要原因。GRACE登记研究显示,患者年龄每增加10岁,AMI死亡率升高近1倍。老年

ESC 2014:射血分数保留的AMI患者长期用β阻滞剂无益?(FAST-MI 2005)

ESC2014公布的FAST-MI研究结果表明,射血分数保留的心肌梗死(AMI)后患者或许不应继续长期应用β受体阻滞剂进行治疗。研究者指出,尚需其它研究尤其是随机对照研究进一步确认该研究结果。 大多数针对β受体阻滞剂在AMI中使用的随机对照研究是于再灌注治疗时代和现代二级预防之前开展的,同样,其在AMI后射血分数保留患者中的使用价值也存在争议。最近的ACC/AHA关于ST段抬高型心肌梗死(STE

心脏支架被“滥用”了吗?海内外专家热议

质疑:钟南山院士举例“五个心脏支架”批医德 “广东某医院的一个心脏导管大夫为病人做冠状动脉造影,本来问题不大,但是最后给放了五个支架。”全国人大代表、中国工程院院士钟南山6日下午在广东代表团审议政府工作报告时,痛批当前一些公立医院医生不讲医德、违规创收的行为。 国家卫计委此前公布的数据显示,我国心血管疾病介入诊疗技术近来逐年增加。作为最主要的技术之一的冠心病介入诊疗全年

AMI后心脏损伤全新分级标准意味着什么?

近日,上海交通大学医学院附属仁济医院心内科何奔教授团队,原创性地提出急性心肌梗死(AMI)后心脏损伤的全新分级标准,受到国内外学界的广泛关注。相关成果已在线发表在PLoS ONE杂志(PLoS One. 2015 Jun 19;10(6):e0130158.)。 美国斯坦福医院的David Hsi教授评价:“何奔教授与其团队以心肌梗死(MI)后心脏重构的病理生理机制为向导,利用心脏磁共振(M

EHJ:干细胞治疗改善急性心梗患者5年预后

急性心肌梗死(AMI)后心脏不良重塑及心梗后心衰影响长期临床转归。急性心肌梗死组细胞再灌注和梗死重塑(REPAIR-AMI)研究随访4个月结果表明AMI后冠脉内注射骨髓源性单个核细胞(BMCs)增加左心室射血分数(LVEF),改善心脏收缩功能。但BMCs治疗长期疗效尚不清楚。 为此,REPAIR-AMI研究团队进一步延长随访时间至5年,并分析了5年无不良事件生存的预测因子。研究发现,骨髓源性

Circulation:年轻AMI患者在出院30天内再入院概率和时间的性别差异

背景:年轻的女性(<65岁)急性心肌梗死后比年轻男性(AMI)要有2-3倍更大的死亡风险。如果这会因年龄而异,尚不清楚他们30天内再入院的风险是否会更高。研究人员考察了这种概率,时间和30天再入院主要诊断的性别差异,包括调整混杂因素的独立性的影响。    方法和结果:该研究包括年龄18-64岁的主要诊断为急性心肌梗死患者。数据是从加利福尼亚的医疗保健费用和项目国家住院